Collaborative Research and License Agreements - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended				3 Months Ended			12 Months Ended
	Dec. 31, 2021	Sep. 30, 2021	Oct. 31, 2017	Jul. 31, 2016	Mar. 31, 2024	Mar. 31, 2023	Jun. 30, 2022	Dec. 31, 2016	Mar. 31, 2007
Research And Development Arrangement Contract To Perform For Others [Line Items]
Research and Development Expense					$ 56,492	$ 34,054
Incyte Agreement [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Common stock shares purchased	1,421,523
Purchase price per share	$ 24.62
Proceeds from issuance of common stock	$ 35,000
Collaboration receivable					4,000
Collaboration expense due to counterparty					11,500
Incyte Agreement [Member] | Maximum [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Potential milestone payments to be made		$ 220,000
Commercialization milestones and tiered royalties		$ 230,000
Incyte Agreement [Member] | Non-Refundable Cash Payments [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Upfront milestone payable	$ 117,000
Allergan License Agreement [Member] | Vitae Pharmaceuticals Inc [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Potential milestone payments to be made			$ 99,000
Aggregate Potential Milestone Payable			$ 70,000
Milestone Expenses Paid					8,000
Development and regulaotry milestones Expenses					16,000
License Agreements Expiration Period			10 years
Ucb License Agreement [Member] | U C B Biopharma [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Research and Development Expense					$ 10,000		$ 16,000	$ 5,000
Potential milestone payments to be made				$ 119,500
Aggregate Potential Milestone Payable				$ 250,000
License Agreements Expiration Period				10 years
Milestone Payment Due							$ 5,800
License Agreement [Member] | Bayer Pharma Ag [Member] | Maximum [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Aggregate payment obligation									$ 150,000
Global and U.S. [Member] | Incyte Agreement [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Development costs associated with clinical trials		45.00%
Global and U.S. [Member] | Incyte Agreement [Member] | Incyte Corporation [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Development costs associated with clinical trials		55.00%
Ex-U.S. Countries [Member] | Incyte Agreement [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Development costs associated with clinical trials		100.00%